Natural Killer Cells Reconstitution Kinetics Post Haploidentical Transplantation

Peking University

Status: Unknown

Conditions: Natural Killer Cell Mediated Immunity

Treatments: Drug: MMF

Study type: Observational

Funder types: Other

Identifiers

NCT02978274

2016PHB038-01

Details and patient eligibility

About

Patients undergoing haploidentical allo-HSCT will be prospectively enrolled exploring the NK cells phenotype and functional reconstitution.

Full description

Patients with hematological malignancies suitable for allo-HSCT but without HLA-identical related or unrelated donors were candidates for the HLA-haploidentical HSCT. Patients undergoing haploidentical allo-HSCT will be prospectively enrolled exploring the NK cells phenotype and functional reconstitution. Peripheral blood will be collected by day15, 30, 60, 90, 180, and 1 year post transplantation.

Enrollment: 200 estimated patients

Sex: All

Ages: 15 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• AML or MDS or CML or ALL undergoing haploidentical stem cells transplantation

Exclusion criteria

• NR or refractory AML/ALL before transplantation donors from mother or collateral related

Trial design

200 participants in 2 patient groups

experimental group

Description:

MMF withdrawal by engraftment post haplo-SCT

Treatment:

Drug: MMF

Drug: MMF

control group

Description:

MMF withdrawal by 2 month post haplo-SCT

Treatment:

Drug: MMF

Drug: MMF